The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

XDS

Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463

Refinement of Macromolecular Structures by the Maximum-Likelihood Method

Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796

MOLREP : an Automated Program for Molecular Replacement

Vagin, A. A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,756

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930

Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function

Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816

Close encounter of the covalent kind: Inhibiting MCL1’s proapoptotic activity with covalent inhibitors

Lessene, G. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.94 · Cited by 1

ER shaping proteins regulate mitochondrial fission, outer membrane permeabilization and apoptosisPreprint

Milani, M., Cohen, G. M., & Varadarajan, S. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/340448 · Cited by 1

Targeting the STAT5 pathway in Ph+ acute lymphoblastic leukemia

Minieri, V., Dominici, M. D., Nevalainen, M. T., & Calabretta, B. (2018) · Oncotarget · doi:10.18632/oncotarget.26412 · Cited by 1

Fragment‐Based Lead Discovery

Hubbard, R. E. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc265 · Cited by 1

[Cardiopulmonary effects of CPPV (continuous positive pressure ventilation) and IRV (inverse ratio ventilation) in experimental myocardial ischemia].

Hachenberg, T., Meyer, J., Sielenkämper, A. W., Kraft, W., Vogt, B., Breithardt, G., & Lawin, P. (1993) · PubMed · Cited by 1

Metabolic reprogramming provides a novel approach to overcome resistance to BH3-mimetics in Malignant Pleural MesotheliomaPreprint

Sun, X.-M., Miles, G. J., Powley, I. R., Craxton, A., Galavotti, S., Chernova, T., Dawson, A., Nakas, A., Willis, A. E., Cain, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.31.534530 · Cited by 1

Pharmacologic Features of Drugs Targeting BCL 2 Family Members

Lue, J. K., & O’Connor, O. A. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch11 · Cited by 1

Antimitotic chemotherapy promotes tumor NF-kB secretory phenotype and immunosuppressive CXCR2+ neutrophils chemotaxis in triple-negative breast cancersPreprint

Chocteau, F., Gautier, F., Josso, V., Douillard, E., Juin, P. P., & Barillé‐Nion, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.21.629876 · Cited by 1

Engineered Allosteric RNA Editors Enable Compact, Stimulus-Responsive Post-Transcriptional CircuitsPreprint

Marzilli, A. M., & Ngo, J. T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.29.702378 · Cited by 1

Mutant TP53 Hotspot Variants Differentially Rewire the Caspase Regulatory Network Across Cancer Lineages: A Pan-Cancer Computational Pharmacology AnalysisPreprint

Venkatesan, D. (2026) · Research Square · doi:10.21203/rs.3.rs-9309751/v1 · Cited by 1

Breaking up a pro-survival interaction

Flemming, A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.139

Breaking up a pro-survival interaction

Flemming, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.250

In the absence of apoptosis, myeloid cells arrest when deprived of growth factor, but remain viable by consuming extracellular glucose

Dong, L., Reljic, B., Cheung, J. G., Ng, E. S., Lindqvist, L. M., Elefanty, A. G., Vaux, D. L., & Tran, H. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0275-z

Multi-drug therapy in breast cancer: are there any alternatives?

Mitra, P. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.16

A triple drug combination as a novel anti-glioma therapy?

Zhang, Y., Karpel‐Massler, G., & Siegelin, M. D. (2018) · Oncotarget · doi:10.18632/oncotarget.26279

Advances in Acute Myeloid Leukemia Stem Cells

Yang, X., Xu, X., Liu, Y., Gong, A., Wang, D., Liao, X., & Zhu, H. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84263

Revealing a Non-canonical Role of Anti-apoptotic MCL-1 in Early Embryonic Development

Yang, X. (2017) · doi:10.21007/etd.cghs.2017.0443

A luciferase-based assay identifies niclosamide derivatives antagonizing Mcl-1 through post-translational down-regulationPreprint

Liu, Q., Atkinson, J. M., Gebru, M. T., Clements, K. E., Moldovan, G., & Wang, H. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/665505

Selective Small Molecule Myeloid Cell Leukemia-1 (MCL-1) Inhibitors: Novel Agents in Cancer Therapy

Ibrahim, H., Lasheen, D. S., Serya, R. A. T., & Abu-ELElla, D. (2019) · Archives of Pharmaceutical Sciences Ain Shams University · doi:10.21608/aps.2019.14995.1006

Combinatorial Genetic Screening in Cancer

Najm, F. J. (2019) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)

BH3 Mimetic Drugs for Anti-fibrotic Therapy

Lagares, D. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015783-00235

Pre-Clinical Assessment of MCL-1 as a Therapeutic Target in T-Cell Lymphomas

Christie, A. L. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)

Explorando o metabolismo como ferramenta para investigação e tratamento de doenças

Ferreira, V. G. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.75.2020.tde-03072020-092108

Mechanisms of BAK Activation in the Initiation of Mitochondrial Apoptosis

Singh, G. (2020) · doi:10.21007/etd.cghs.2020.0508

Understanding and drugging the Bcl-2 transmembrane interactome for tumor treatment

Lucendo, E. (2020) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/155914

Discovery and Development of Mcl-1 Inhibitors as Anti-cancer Therapeutics: Hit to Clinical Candidate Optimization

Kump, K. J., & Nikolovska‐Coleska, Z. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016544-00171

Preclinical Evaluation of a Novel Anti-leukemic Mechanism

Zarabi, S. F. (2020) · TSpace (University of Toronto)

Shikonin treatment ameliorates Lipopolysaccharides (LPS) induced acute liver failure in mice via regulating the miR-106/MCL1 and miR-34a/SIRT1/TP53 signaling

Huang, F., Hai, H., & Gao, B. (2021) · Archives of Medical Science · doi:10.5114/aoms/127659

A precision approach to breast cancer treatment based on cell lineage-specific vulnerabilities

Desgrosellier, J. S. (2021) · Oncoscience · doi:10.18632/oncoscience.538

El régimen de sucesiones

Vicente, F. G. (2002) · Anales: Anuario del centro de la UNED de Calatayud

A matter of life or death: targeting MCL-1 in multiple myeloma

Slomp, A. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/323

The Australasian Cell Death Society (ACDS): celebrating 50 years of Australasian cell death research

Speir, M., Chan, A. H., Simpson, D. S., Khan, T., Saunders, T. L., Poon, I. K. H., & Atkin‐Smith, G. K. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12510

Flow fluctuations and the local flowrule of granular suspensions

Wandersman, É., Dijksman, J. A., de Groot, W. A., & van Hecke, M. (2010) · Bulletin of the American Physical Society

Forligsmæssig afskedigelse. Afgørelsesbegrebet i forvaltningsloven

jasv (1998)

Szelektív MCL-1 inhibitorok felfedezése

Kotschy, A. (2021) · Magyar kémiai folyóirat, Kémiai közlemények · doi:10.24100/mkf.2021.02.75

2-Oxy-3-Phenylacrylic Acid Derivatives as Potent Mcl-1 Inhibitors for Treatment of Cancer

Xi, J., Yao, L., Zhang, R., Chen, K., Li, M., Zhang, D., Cui, M., Nie, H., Wang, P., Li, X., et al. (2021) · Results in Chemistry · doi:10.1016/j.rechem.2022.100308

A Functional Pre-Screening Platform for Identifying Points of Vulnerability in the Cell Death Map of Human Melanoma Tumors

Dekel‐Bird, N. P., Bialik, S., Itzhaki, O., Salame, T. M., Yaeli-Slonim, N., Levin‐Salomon, V., Dasari, S. K., Besser, M. J., & Kimchi, A. (2022) · Journal of Cancer Science and Clinical Therapeutics · doi:10.26502/jcsct.5079145

Targeting pro-survival cell signaling pathways in multiple myeloma

Spaan, I. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1172

Evaluation of BH3 mimetics as a novel therapeutic strategy in acute myeloid leukemia

Ewald, L. (2021) · doi:10.21248/gups.62410

The MacroScreen Platform

Fontaine, M. A. C. (2020) · doi:10.26481/dis.20200514mf

The Heme-Regulated Inhibitor Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-Mimetics

Smith, K. (2021) · doi:10.21007/etd.cghs.2021.0529

Faculty Opinions recommendation of A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.

Che, Y. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737014723.793569231

Faculty Opinions recommendation of Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens.

Pan‐Hammarström, Q., & Zhang, B. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732320295.793542024

Faculty Opinions recommendation of Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer.

Gandhi, V. V. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734083263.793564477

Faculty Opinions recommendation of What do editors do? Understanding the physiological functions of A-to-I RNA editing by adenosine deaminase acting on RNAs.

Vicens, Q. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738236003.793576348

A novel MDM2-p53 antagonist APG115 exerts synergistic effect with ibrutinib via targeting MCL-1 in chronic lymphocytic leukemiaPreprint

Han, Y., Hu, X., Wang, H., Tian, Z., Zhang, X., Hu, S., Zhang, Y., & Wang, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1983828/v1

Molecular dynamics studies of CED ‐4/ CED ‐9/ EGL ‐1 ternary complex reveal CED ‐4 release mechanism in the linear apoptotic pathway of Caenorhabditis elegans

Reddy, C. N., & Sankararamakrishnan, R. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26457

Patients in Focus: What’s Relevant for Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia?

Etheridge, S. (2017) · EMJ Hematology · doi:10.33590/emjhematol/10312026

Data from Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

Zañudo, J. G. T., Mao, P., Alcon, C., Kowalski, K. J., Johnson, G. N., Xu, G., Baselga, J. M., Scaltriti, M., Letai, A. G., Montero, J., et al. (2023) · doi:10.1158/0008-5472.c.6513486.v1

Data from Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

Zañudo, J. G. T., Mao, P., Alcon, C., Kowalski, K. J., Johnson, G. N., Xu, G., Baselga, J. M., Scaltriti, M., Letai, A. G., Montero, J., et al. (2023) · doi:10.1158/0008-5472.c.6513486

Data from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression

Tanimoto, A., Matsumoto, S., Takeuchi, S., Arai, S., Fukuda, K., Nishiyama, A., Yoh, K., Ikeda, T., Furuya, N., Nishino, K., et al. (2023) · doi:10.1158/1078-0432.c.6529862

Data from AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells

Cidado, J. R., Boiko, S., Proia, T. A., Ferguson, D., Criscione, S. W., Martin, M. S., Pop-Damkov, P., Su, N., Franklin, V. N. R., Chilamakuri, C. S. R., et al. (2023) · doi:10.1158/1078-0432.c.6528438

Data from Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner

Liu, T., Lam, V., Thieme, E., Sun, D., Wang, X., Xu, F., Wang, L., Danilova, O. V., Xia, Z., Tyner, J. W., et al. (2023) · doi:10.1158/1078-0432.c.6530699.v1

Data from AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells

Cidado, J. R., Boiko, S., Proia, T. A., Ferguson, D., Criscione, S. W., Martin, M. S., Pop-Damkov, P., Su, N., Franklin, V. N. R., Chilamakuri, C. S. R., et al. (2023) · doi:10.1158/1078-0432.c.6528438.v1

Supplementary Table 1 from CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors

Xu, Z., Vandenberg, C. J., Lieschke, E., Rago, L. D., Scott, C. L., & Majewski, I. J. (2023) · doi:10.1158/1541-7786.22526957.v1

Supplementary Table 2 from CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors

Xu, Z., Vandenberg, C. J., Lieschke, E., Rago, L. D., Scott, C. L., & Majewski, I. J. (2023) · doi:10.1158/1541-7786.22526954

Supplementary Figure 2 from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma

Dalton, K. M., Krytska, K., Lochmann, T. L., Sano, R., Casey, C., D'Aulerio, A., Khan, Q. A., Crowther, G. S., Coon, C. M., Cai, J., et al. (2023) · doi:10.1158/1535-7163.22522659.v1

Data from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma

Dalton, K. M., Krytska, K., Lochmann, T. L., Sano, R., Casey, C., D'Aulerio, A., Khan, Q. A., Crowther, G. S., Coon, C. M., Cai, J., et al. (2023) · doi:10.1158/1535-7163.c.6543453

Data from Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia

Kamachi, K., Ureshino, H., Watanabe, T., Yoshida‐Sakai, N., Fukuda‐Kurahashi, Y., Kawasoe, K., Hoshiko, T., Yamamoto, Y., Kurahashi, Y., & Kimura, S. H. (2023) · doi:10.1158/2767-9764.c.6551193

Principles for Understanding Mechanisms of Cell Death and Their Role in Cancer Biology

Diepstraten, S. T., Marca, J. E. L., Huang, A. D. C. S., & Kelly, G. L. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch10

Data from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway

Lee, I., Doepner, M., Weissenrieder, J., Majer, A. D., Mercado, S., Estell, A., Natale, C. A., Sung, P. J., Foskett, J. K., Carroll, M. P., et al. (2023) · doi:10.1158/2767-9764.c.6749782

Does the Glandular Tolerant to McL-1 Inhibitor S63845?

Chang, X. (2023) · MedScien · doi:10.61173/5sd16q58

Overexpression of MCL-1 provides OCI-Ly1 with resistance toVenetocalx

Zhang, X. (2023) · MedScien · doi:10.61173/6p9d7k08

In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia

Gill, H., & Yip, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_16

The Role of BCL-2/MCL-1 Targeting in Acute Myeloid Leukemia

Tang, K., & Chan, S. M. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_10

Additional file 1 of Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax

Gaur, T., Poddutoori, R., Khare, L., Bagal, B. P., Rashmi, S., Patkar, N. V., Tembhare, P. R., Subramanian, P. G., Shetty, D. L., Dutt, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23803051

Additional file 2 of Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax

Gaur, T., Poddutoori, R., Khare, L., Bagal, B. P., Rashmi, S., Patkar, N. V., Tembhare, P. R., Subramanian, P. G., Shetty, D. L., Dutt, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23803054

Additional file 3 of Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax

Gaur, T., Poddutoori, R., Khare, L., Bagal, B. P., Rashmi, S., Patkar, N. V., Tembhare, P. R., Subramanian, P. G., Shetty, D. L., Dutt, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23803057

Apoptosis Resistance in Solid Tumours: A Potential Therapeutic Target in Gastric Carcinoma?

Butterworth, W. A., Griffiths, E. A., & Shannon-Lowe, C. D. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_320

Evaluation of Antifibrotic Mechanisms of 3′5-Dimaleamylbenzoic Acid on Idiopathic Pulmonary Fibrosis: A Network Pharmacology and Molecular Docking Analysis

González-García, K., Santos-Álvarez, J. C., Velázquez-Enríquez, J. M., Zertuche-Martínez, C., Reyes-Jiménez, E., Baltiérrez‐Hoyos, R., & Vásquez-Garzón, V. R. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3040048

Elevated MCL1 expression drives esophageal squamous cell carcinoma stemness and induces resistance to radiotherapy

Chen, J., Chen, G., Fang, X., Sun, J., Song, J., & Chen, Z. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-2024-2027

Exploring the Anti-Tumor Effects of Brusatol in Aggressive B-Cell LymphomasPreprint

Szmyra, M., Haingartner, S., Jantscher, S., Bernhart, E. M., Kovács-Hajdu, P., Bošková, V., Krall, N., Zupo, A., Pircher, T., Pansy, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.16.649058

Therapy resistance in AML is mediated by cytoplasmic sequestration of the transcriptional repressor IRF2BP2Preprint

Althoff, M. J., Minhajuddin, M., Stevens, B. M., Gillen, A. E., Gipson, S., Patel, S. B., Shelton, I. T., Miller, R., Vujovic, A., Krug, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.22.655396

Linking Fluorine with Bio-Derived Furfural: Aiming Towards More Sustainable Fluorinated Polymers and Drugs

Galkin, K. I., & Sandulenko, I. V. (2025) · Molecules · doi:10.3390/molecules30112305

Synthesis and biological studies on ovarian cancer cells of new heterocyclic molecules inspired by MIM1, an inhibitor of the anti-apoptotic protein Mcl-1

Pezeril, J., Weiswald, L., Soulieman, A., Paysant, H., Hachem, A., Brotin, É., Denoyelle, C., Voisin‐Chiret, A. S., Gouault, N., Gree, R. L., et al. (2025) · New Journal of Chemistry · doi:10.1039/d5nj00175g

Sensitivity to an inhibitor of translation elongation in solid and hematologic cancers

Gomes, N. P., Frederick, B. A., Tentler, J. J., & Su, T. T. (2025) · Scientific Reports · doi:10.1038/s41598-025-06273-6

Alisertib and Barasertib Induce Cell Cycle Arrest and Mitochondria-Related Cell Death in Multiple Myeloma with Enhanced Efficacy Through Sequential Combination with BH3-Mimetics and Panobinostat

Benedi, A., Beltrán‐Visiedo, M., Jiménez‐Alduán, N., del Valle, A. S., Anel, A., Naval, J., & Marzo, I. (2025) · Cancers · doi:10.3390/cancers17142290 · Cited by 2

Blocking β-adrenergic receptor signaling enhances the sensitivity of AML to MCL-1 inhibitor S63845

Kuang, W., Zeng, C., Xie, Q., Zhou, M., Li, X., Wu, B., Lan, Y., Liu, W., Zhou, G., & Cao, S. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123894

A magyar gyógyszerkutatás és -fejlesztés a 21. Században

Greiner, I., Kotschy, A. M., Volk, B., & Keserû, M. G. (2025) · Magyar Tudomány · doi:10.1556/2065.186.2025.8.2

Small Molecule Inhibitors Targeting Protein–Protein Interactions in the BCL Protein

Zhu, W., He, Y., Chen, G., & Zhu, D. (2025) · Wiley eBooks · doi:10.1002/9783527845828.ch12

Synergistic targeting of MCL1 and caspases for enhanced anti-tumor immunity in breast cancerPreprint

Yi, J. K., Lee, J., Kim, P., Shaw, L. M., & Spektor, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.10.681458

Novel therapeutic interventions to overcome drug resistance in cancer: targeting key regulators of the apoptotic pathway

Kanwar, N., Kumar, A. H. S., Gupta, N., Gagneja, G., & Kanwal, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33343-9.00008-9

Mitochondrial integrated stress response activation creates a therapeutic vulnerability to MCL-1 inhibition in acute myeloid leukemia

Brakefield, L., Budhraja, A., Hall, P. A., Brewington, D., Moore, J., Lott, J., Ni, Y., Voronin, D., Grant-Chapman, O., Mukiza, T. O., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09037-w

Additional file 2 of Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas

Müller, D., Mazzeo, P., Koch, R., Bösherz, M.-S., Welter, S., von Hammerstein-Equord, A. F., Hinterthaner, M., Cordes, L., Belharazem, D., Marx, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17020815

Additional file 1 of Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas

Müller, D., Mazzeo, P., Koch, R., Bösherz, M.-S., Welter, S., von Hammerstein-Equord, A. F., Hinterthaner, M., Cordes, L., Belharazem, D., Marx, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17020809

Additional file 1 of Differential expression pattern of Bcl-2 family members in B and T cells in systemic lupus erythematosus and rheumatoid arthritis

Kielbassa-Elkadi, K., van der Weele, L., Ae, V., de Vries, N., Eldering, E., & Kuijpers, T. (2023) · Figshare · doi:10.6084/m9.figshare.24628102

Additional file 1 of A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells

Zhao, T., He, Q., Xie, S., Zhan, H., Jiang, C., Lin, S., Liu, F., Wang, C., Chen, G., & Zeng, H. (2023) · Figshare · doi:10.6084/m9.figshare.22603577

Additional file 1 of Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells

Zhao, H., Jiang, Y., Lin, F., Zhong, M., Tan, J., Zhou, Y., Liu, L., Li, G., Deng, M., & Xu, B. (2022) · Figshare · doi:10.6084/m9.figshare.19785676

Additional file 4 of Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax

Gaur, T., Poddutoori, R., Khare, L., Bagal, B., Rashmi, S., Patkar, N., Tembhare, P. R., Subramanian, P. G., Shetty, D., Dutt, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23803060

Mechanistic Insights into Luteolin’s Effect on Gastric Cancer: Inhibition of MCL1 and Its Impact on PI3K-Akt and JAK-STAT Signaling

Zhang, X.-F., Zhang, M.-M., Yan, P.-Z., Shi, X., Li, Y.-Q., & Jia, B. (2025) · World Journal of Traditional Chinese Medicine · doi:10.4103/wjtcm.wjtcm_28_25

Visomitin as a differentiation-inducing therapeutic agent through SYK inhibition in AML

Jeon, B.-E., Kwon, C.-S., Lee, J.-E., Lee, S.-J., Cho, Y., Shin, H., Kim, S., & Jung, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1741351 · Cited by 1

Inhibition of BIRC5 and MCL-1 as a potential treatment strategy to overcome drug resistance in Mantle Cell Lymphoma

Pfitzer, J. C., Chakravarti, S., Mazumder, S., Fengzhi, L. I., Mukherjee, U. K., & Mitra, A. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01467-1

Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance

Li, C., Chang, Y.-H., Maki, M., Omori, I., Sato, N., Goyama, S., Kitamura, T., & Enomoto, Y. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0986

Conception, synthèse et évaluation biologique d’inhibiteurs des protéines anti-apoptotiques de la famille Bcl-2

Samra, A. A. (2017) · doi:10.70675/b102c54fzd500z453ez82dfzc60e29a02c7b

Régulation de la stabilité de la protéine anti-apoptotique BCL2A1

Lionnard, L. (2018) · theses.fr (ABES) · doi:10.70675/1eec02ffz98dez4a56z98e2z389a2cd8558d

Propagation d'un signal pro-apoptotique paracrine via la voie cGAS/STING lors des chimitothérapies antimitotiques

Lohard, S. (2019) · doi:10.70675/10e179e8zfcc6z4481zbb4bzafeef9c41257

Influence des fibroblastes associés aux cancers (CAFs) sur la résistance à l'apoptose des cancers du sein

Louault, K. (2018) · theses.fr (ABES) · doi:10.70675/0aef1137z5689z4922z8455zdbe4b757612c

Identification par séquençage de l'exome de la dérégulation des voies de signalisation dans le myélome multiple et leurs conséquences fonctionnelles, notamment sur la voie p53

Tessoulin, B. (2018) · theses.fr (ABES) · doi:10.70675/07321990z15cbz44b0zba91zeee1f3067f1f

ID Card of Mcl-1 PROTAC degrader: From in silico design to biological validation in chemoresistant ovarian cancer

Cornu, M., Pezeril, J., Guedeney, N., Paysant, H., Lemaitre, T., Schwalen, F., Florent, R., N’Guyen, J., Corvaisier, S., Since, M., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100336

Exploration des récepteurs à dépendance dans les hémopathies malignes

Fahed, D. (2020) · theses.fr (ABES) · doi:10.70675/621dee0ez6dd8z4539z81a4z388f4a3296af

MCL1 Can Be Targeted to Induce Apoptosis in Multiple Cancer Types

(2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2016-207

Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

Maragno, A. L., Mistry, P., Kotschy, A., Szlavik, Z., Murray, J., Davidson, J. E. P., Toumelin-Braizat, G. L., Chanrion, M., Bruno, A., Clapéron, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4482 · Cited by 15

Development and Characterization of Novel Mcl-1 Inhibitors for Treatment of Cancer.

Mady, A. S. A. (2016) · Deep Blue (University of Michigan) · Cited by 1

Targeting MCL-1 in cancer: current status and perspectives

Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 318

Targeting MCL‐1 to Overcome Therapeutic Resistance and Improve Cancer Mortality

Mohiuddin, M. (2025) · Health Science Reports · doi:10.1002/hsr2.71390 · Cited by 9